Takeda Receives FDA Approval for Subcutaneous Entyvio as UC Maintenance Therapy
The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory...
Neusoft Medical’s NeuRT Aurora Receives NMPA Approval for Advanced Radiotherapy Platform
Neusoft Medical Systems Co., Ltd, a leading player in the medical technology sector, has announced...
CStone Pharmaceuticals’ PDGFRA Mutation Detection Kit Receives NMPA Approval
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received marketing...
RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy
China-based RemeGen Ltd (HKG: 9995) is poised to conduct a Phase II clinical study in...
Eli Lilly’s Insulin Biosimilar YouBiAn Approved for Diabetes Treatment in China
US pharmaceutical major Eli Lilly (NYSE: LLY) has announced that it has received market approval...
Everest Medicines’ Xerava Receives Marketing Approval from TFDA for cIAI Treatment
Everest Medicines (HKG: 1952) has announced that it has received marketing approval for its antibiotic...
Sino Medical Sciences Receives Turkish Approval for HT Supreme Drug-Eluting Stent System
Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...
Konruns Pharmaceutical’s KC1036 Pediatric Indication Accepted for NMPA Review
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced that the National Medical Products Administration...
Elpiscience Biopharmaceuticals Initiates Phase I Trial for Anti-LILRB2 Antibody ES009
Elpiscience Biopharmaceuticals, a China-based biopharmaceutical company, has announced that the first patient has been dosed...
Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline
China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured...
Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH
Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval...
ImmuneOnco Initiates Phase I Trial for CD24-Targeted Monoclonal Antibody IMM47
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the first patient dosing in a...
MitrAssist Lifesciences Secures $100 Million in Series C Financing for Cardiovascular Devices
MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD...
Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first...
LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China
Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study...
Beijing Insurance Bureau Launches Pilot to Boost Access to NRDL Drugs
The Beijing Municipal Medical Insurance Bureau has announced the initiation of pilot work aimed at...
Beijing-Tianjin-Hebei Region Initiates Drug VBP with 37 Medicines, Including Biologics
The Beijing Municipal Medical Insurance Bureau has issued a notification to commence the drug volume-based...
Regeneron Pharmaceuticals Acquires Decibel Therapeutics to Advance Hearing Loss Treatments
Regeneron Pharmaceuticals (NASDAQ: REGN) has completed the acquisition of Decibel Therapeutics, a developer of gene...
Novo Nordisk Partners with Valo Health to Develop Cardiometabolic Disease Therapies
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a strategic partnership with US company...
Coherus Biosciences Awaits FDA Decision on Toripalimab with Year-End Approval Forecast
Coherus Biosciences Inc., (NASDAQ: CHRS), a US-based biotechnology company, has provided an update on the...